CA3092169A1 - Pd1 binding agents - Google Patents
Pd1 binding agents Download PDFInfo
- Publication number
- CA3092169A1 CA3092169A1 CA3092169A CA3092169A CA3092169A1 CA 3092169 A1 CA3092169 A1 CA 3092169A1 CA 3092169 A CA3092169 A CA 3092169A CA 3092169 A CA3092169 A CA 3092169A CA 3092169 A1 CA3092169 A1 CA 3092169A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803745.7A GB201803745D0 (en) | 2018-03-08 | 2018-03-08 | PD1 binding agents |
| GB1803745.7 | 2018-03-08 | ||
| GB1807176.1 | 2018-05-01 | ||
| GBGB1807176.1A GB201807176D0 (en) | 2018-03-08 | 2018-05-01 | PD1 Binding agents |
| GB1811302.7 | 2018-07-10 | ||
| GBGB1811302.7A GB201811302D0 (en) | 2018-03-08 | 2018-07-10 | PD1 binding agents |
| GB1816372.5 | 2018-10-08 | ||
| GBGB1816372.5A GB201816372D0 (en) | 2018-03-08 | 2018-10-08 | PD1 binding agents |
| GB1817652.9 | 2018-10-29 | ||
| GBGB1817652.9A GB201817652D0 (en) | 2018-03-08 | 2018-10-29 | PD1 binding agents |
| PCT/EP2019/055901 WO2019170885A1 (en) | 2018-03-08 | 2019-03-08 | Pd1 binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092169A1 true CA3092169A1 (en) | 2019-09-12 |
Family
ID=61972774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092169A Pending CA3092169A1 (en) | 2018-03-08 | 2019-03-08 | Pd1 binding agents |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10858434B2 (enExample) |
| EP (1) | EP3762418A1 (enExample) |
| JP (1) | JP7419238B2 (enExample) |
| KR (1) | KR20200128544A (enExample) |
| CN (1) | CN111819201A (enExample) |
| AU (1) | AU2019229663A1 (enExample) |
| CA (1) | CA3092169A1 (enExample) |
| GB (5) | GB201803745D0 (enExample) |
| IL (1) | IL277131A (enExample) |
| SG (1) | SG11202008240RA (enExample) |
| WO (1) | WO2019170885A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201914747D0 (en) * | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN116194471A (zh) | 2020-06-23 | 2023-05-30 | 卡德门企业有限公司 | 抗pd-1抗体和融合蛋白 |
| EP4353746A4 (en) * | 2021-06-11 | 2024-12-04 | Guangdong Fapon Biopharma Inc. | Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof |
| US11981727B2 (en) * | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| CN116253796A (zh) * | 2022-09-21 | 2023-06-13 | 三优生物医药(上海)有限公司 | 靶向冠状病毒的中和抗体、其抗原结合片段及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218257A (zh) * | 2005-03-25 | 2008-07-09 | 托勒克斯股份有限公司 | Gitr结合分子及其用途 |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) * | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MA43028B1 (fr) * | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
-
2018
- 2018-03-08 GB GBGB1803745.7A patent/GB201803745D0/en not_active Ceased
- 2018-05-01 GB GBGB1807176.1A patent/GB201807176D0/en not_active Ceased
- 2018-07-10 GB GBGB1811302.7A patent/GB201811302D0/en not_active Ceased
- 2018-10-08 GB GBGB1816372.5A patent/GB201816372D0/en not_active Ceased
- 2018-10-29 GB GBGB1817652.9A patent/GB201817652D0/en not_active Ceased
-
2019
- 2019-03-08 WO PCT/EP2019/055901 patent/WO2019170885A1/en not_active Ceased
- 2019-03-08 SG SG11202008240RA patent/SG11202008240RA/en unknown
- 2019-03-08 AU AU2019229663A patent/AU2019229663A1/en not_active Abandoned
- 2019-03-08 EP EP19710388.0A patent/EP3762418A1/en not_active Withdrawn
- 2019-03-08 CA CA3092169A patent/CA3092169A1/en active Pending
- 2019-03-08 CN CN201980017469.7A patent/CN111819201A/zh active Pending
- 2019-03-08 KR KR1020207027823A patent/KR20200128544A/ko not_active Withdrawn
- 2019-03-08 JP JP2020542297A patent/JP7419238B2/ja active Active
-
2020
- 2020-06-25 US US16/911,826 patent/US10858434B2/en not_active Expired - Fee Related
- 2020-09-03 IL IL277131A patent/IL277131A/en unknown
- 2020-11-02 US US17/086,762 patent/US11851460B2/en active Active
-
2023
- 2023-11-14 US US18/508,501 patent/US20240124590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10858434B2 (en) | 2020-12-08 |
| US20210047415A1 (en) | 2021-02-18 |
| GB201803745D0 (en) | 2018-04-25 |
| GB201807176D0 (en) | 2018-06-13 |
| GB201816372D0 (en) | 2018-11-28 |
| JP7419238B2 (ja) | 2024-01-22 |
| EP3762418A1 (en) | 2021-01-13 |
| IL277131A (en) | 2020-10-29 |
| JP2021515542A (ja) | 2021-06-24 |
| AU2019229663A1 (en) | 2020-10-15 |
| SG11202008240RA (en) | 2020-09-29 |
| US11851460B2 (en) | 2023-12-26 |
| KR20200128544A (ko) | 2020-11-13 |
| US20200317785A1 (en) | 2020-10-08 |
| GB201817652D0 (en) | 2018-12-12 |
| WO2019170885A1 (en) | 2019-09-12 |
| US20240124590A1 (en) | 2024-04-18 |
| CN111819201A (zh) | 2020-10-23 |
| GB201811302D0 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260015420A1 (en) | Cd47 binding agents | |
| AU2019219312B2 (en) | C-kit antibodies | |
| US20240124590A1 (en) | Pd1 binding agents | |
| US10858435B2 (en) | PD1 binding agents | |
| US12415861B2 (en) | Anti C-MET antibodies | |
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| CA3289307A1 (en) | Pd1 and vegfr2 dual-binding agents | |
| US11655300B2 (en) | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240306 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20241205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250619 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250717 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251104 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260130 Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260521 |